The safety and efficacy of Brintellix was established in a comprehensive clinical trial program that included seven pivotal studies: six 6–8 week short-term studies and one 24–64 week long-term maintenance study that demonstrated statistically significant improvements in overall symptoms of depression in adults with MDD.
The mechanism of which vortioxetine exerts its antidepressant effects is not fully understood, but is thought to be related to its enhancement of serotonergic activity in the CNS through inhibition of the reuptake of serotonin. Vortioxetine is also an agonist at 5-HT1A receptors, a partial agonist at 5-HT1B receptors and an antagonist at 5-HT3, 5-HT1D, and 5-HT7 receptors.
Brintellix is available in 5mg, 10mg, and 20mg strength tablets.
For more information call (877) 825-3327 or visit Brintellix.com.